UKG489B
Total Payments
$11,030
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $11,030 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,030 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FIRST IN HUMAN OPEN LABEL AND SINGLE DOSE STUDY TO ASSESS SAFETY AND TOLERABILITY OF TOPICAL OTIC ADMINISTRATION OF UKG489 IN ADULT HEALTHY VOLUNTEERS | Novartis Pharmaceuticals Corporation | $11,030 | 0 |
Top Doctors Receiving Payments for UKG489B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charleston, SC | $11,030 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $11,030
- Total Doctors 0
- Transactions 1
About UKG489B
UKG489B is a drug associated with $11,030 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2017. In 2017, $11,030 was paid across 1 transactions to 0 doctors.
The most common payment nature for UKG489B is "Unspecified" ($11,030, 100.0% of total).
UKG489B is associated with 1 research study, including "A FIRST IN HUMAN OPEN LABEL AND SINGLE DOSE STUDY TO ASSESS SAFETY AND TOLERABILITY OF TOPICAL OTIC ADMINISTRATION OF UKG489 IN ADULT HEALTHY VOLUNTEERS" ($11,030).